Recognition of the Major Cat Allergen Fel d 1 through the Cysteine-rich Domain of the Mannose Receptor Determines Its Allergenicity*§

Mohamed Emara1‡, Pierre-Joseph Royer‡, Zaigham Abbas‡, Herb F. Sewell§, Gihan Gabriel Mohamed‡, Sonali Singh‡, Samantha Peel‡, Jane Fox§, Farouk Shakib§, Luisa Martinez-Pomares‡, and Amir M. Ghaemmaghami§

From the 1School of Molecular Medical Sciences, the 2Division of Therapeutics & Molecular Medicine, and the 3Nottingham Respiratory Biomedical Research Unit, Queen’s Medical Centre, The University of Nottingham, Nottingham NG7 2UH, United Kingdom

Dendritic cells are professional antigen-presenting cells that are specialized in antigen uptake and presentation. Allergy to cat has increased substantially in recent years and has been shown to be positively associated with asthma. We have recently shown that the mannose receptor (MR), a C-type lectin expressed by dendritic cells, recognizes various glycoallergens from diverse sources and is involved in promoting allergic responses to a major house dust mite allergen in vitro. Here we investigated the potential role of MR in allergic responses to Fel d 1, a major cat allergen. Fel d 1 binding to MR was confirmed by ELISA. Using blocking, gene silencing (siRNA) experiments, and MR knock-out (MR−/−) cells, we have demonstrated that MR plays a major role in internalization of Fel d 1 by human and mouse antigen-presenting cells. Intriguingly, unlike other glycoallergens, recognition of Fel d 1 by MR is mediated by the cysteine-rich domain, which correlates with the presence of sulfated carbohydrates in natural Fel d 1. WT and MR−/− mice were used to study the role of MR in allergic sensitization to Fel d 1 in vivo. MR−/− mice sensitized with cat dander extract and Fel d 1 produced significantly lower levels of total IgE, Fel d 1-specific IgE and IgG1, the hallmarks of allergic response, compared with WT mice. Our data show for the first time that Fel d 1 is a novel ligand of the cysteine-rich domain of MR and that MR is likely to play a pivotal role in allergic sensitization to airborne allergens in vivo.

Allergic sensitization to aeroallergens, particularly those derived from cat, has increased considerably over the past few decades and has been shown to be positively associated with asthma as a strong predisposing factor (1–4). Dander of the domestic cat (Felis domesticus) is the main source of cat allergen, and five allergenic proteins have been identified so far, namely Fel d 1–Fel d 5, with Fel d 1 being the major immunodominant protein accounting for 60–90% of the total allergenicity of cat dander (5–8).

Dendritic cells (DCs)9 are professional antigen-presenting cells and are key regulators of the immune response (9,10). DCs efficiently sample their microenvironment for foreign antigens through a wide range of receptors; of those receptors, C-type lectin-like receptors appear to be of paramount importance in the recognition and uptake of glycoprotein antigens (11–13). Many of the C-type lectin-like receptors that have been identified on DCs function mainly as antigen uptake receptors, including mannose receptor (MR, CD206) (14–16), DC-SIGN (CD209) (17), and DEC-205 (CD205) (18). MR, a 175-kDa type I integral transmembrane glycoprotein, is a C-type lectin-like receptor abundantly expressed on DCs and known to perform a panoply of functions (19). MR recognizes a wide range of carbohydrates on microbial cell surfaces and mediates endocytic clearance of host derived glycoproteins (20,21). The extracellular portion of MR contains three regions: an NH2-terminal cysteine rich (CR) domain, a fibronectin type II-like domain (FNII), and eight C-type lectin-like domains (CTLDs) followed by a hydrophobic transmembrane region and a short COOH-terminal hydrophilic cytoplasmic domain (20,22).

MR is a multifunctional receptor with two lectin activities, involving Ca2+ dependent recognition of carbohydrates through CTLDs, as well as Ca2+-independent binding of acidic glycans sulfated at positions 3 or 4 via the CR domain (FNII), and eight C-type lectin-like domains (CTLDs) followed by a hydrophobic transmembrane region and a short COOH-terminal hydrophilic cytoplasmic domain (20,22).

The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. S1.

© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

The abbreviations used are: DC, dendritic cells; MR, mannose receptor; CTLD, C-type lectin-like domain; CT, control; CR, cysteine-rich; FNII, fibronectin type II-like domain; MR−/−, MR knock-out; Mo-DC, monocyte-derived dendritic cells; BM-DC, bone marrow-derived dendritic cell; Cy5, Cyanine 5; Ab, antibody.

* This work was supported in part by Asthma UK Research Grant 06/001.
† The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. S1.
‡ Recipient of a Ph.D. scholarship from the Faculty of Pharmacy of Helwan University (Helwan, Egypt).
§ To whom correspondence may be addressed: Division of Immunology, Queen’s Medical Centre, Nottingham NG7 2UH, United Kingdom. Tel.: 44-115-8230772; Fax: 44-115-8230759; E-mail: luisa.m@nottingham.ac.uk.
§ To whom correspondence may be addressed: Division of Immunology, Queen’s Medical Centre, Nottingham NG7 2UH, United Kingdom. Tel.: 44-115-8230772; Fax: 44-115-8230759; E-mail: amg@nottingham.ac.uk.
EXPERIMENTAL PROCEDURES

Generation of Antigen-presenting Cells—Immature monocyte-derived (Mo)-DCs were generated from the blood of healthy individuals (obtained with informed consent and after ethical committee approval) as previously described (29). Briefly, peripheral blood mononuclear cells were separated by standard density gradient centrifugation on Histopaque-1077 (Sigma). Monocytes were then isolated from peripheral blood mononuclear cells using mouse anti-human CD14 mAb conjugated to magnetic beads (Miltenyi Biotec). CD14+ cells were cultured in RPMI 1640 supplemented with 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM l-glutamine (all from Sigma), and 10% low endotoxin FBS (Autogen Bioclear). Monocyte differentiation was carried out for 6 days in the presence of IL-4 (250 IU/ml) and GM-CSF (50 ng/ml) (R & D Systems). Bone marrow-derived dendritic cells (BM-DCs) were generated in culture from WT and MR knock-out mice as described elsewhere (30) with minor modifications. Briefly, bone marrow was isolated from bones of the hind legs (femurs and tibias) washed in 70% ethanol and subsequently in RPMI 1640 medium. The bone marrow was then cultured for 6 days in complete medium (RPMI 1640 containing 10% FBS supplemented with 2 mM l-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin; all from Sigma) in the presence of 1000 units/ml murine GM-CSF (R & D Systems). Bone marrow-derived macrophages were generated as previously described (31). Briefly, bone marrow collected from each mouse was resuspended in complete medium (as previously described for BM-DCs), and macrophages were cultured in complete medium containing L-cell conditioned medium for 6 days. Macrophages were collected by treating cells with cold PBS containing 10 mM EDTA.

Lectin ELISA for the Detection of Fel d 1-MR Binding—Binding of the major cat allergen Fel d 1 to various MR constructs was investigated using ELISA. All washes and incubations were carried out in lectin buffer consisting of 10 mM Tris-HCl, pH 7.5, 10 mM Ca2+, 154 mM NaCl, and 0.05% (w/v) Tween 20. Natural Fel d 1 (Indoor Biotechnologies), affinity-purified from cat hair (32) with >95% purity, was used in all experiments. Fel d 1 (5 µg/ml), as well as 2 µg/ml of MR carbohydrate ligands (Mannan (Sigma), sulfated galactose (SO4-3-Gal-PAA), or Gal-PAA and incubated with CR-Fc for 2 h. Alternatively, inhibition assays were performed by preincubation or not of CR-Fc with different concentrations (0.001, 0.01, 0.1, 1, or 10 µg/ml) of mannann or SO4-3-Gal-PAA for 20 min prior to addition to wells of Maxisorp plates that had previously been coated overnight with 5 µg/ml of Fel d 1. All of the assays were carried out in triplicate.

Glycan Analysis of Fel d 1 Using In-gel Protein Digestion and Nanoflow LC-MS/MS Fourier Transform Ion Cyclotron Resonance—These experiments were carried out in the Proteomics Center of the Sahlgrenska Academy (University of Gothenburg, Gothenburg, Sweden). The method for in-gel protein digestion with trypsin described by Shevchenko et al. (35) was applied with some minor modifications (34). Briefly, the gel pieces were destained by washing three times in 25 mM NH4HCO3 in 50% CH3CN and one time in 25 mM NH4HCO3 in 50% CH3OH. Gel pieces were dried in a vacuum centrifuge and incubated with digestion buffer (50 mM NH4HCO3, 10 ng/µl trypsin) at 37 °C overnight. The peptides were extracted in 50% CH3CN, 1% CH3COOH, and the supernatant was evaporated to dryness in a vacuum centrifuge. Prior to MS analysis, the peptides were reconstituted in 0.2% HCOOH.

Two-microliter sample injections were made with an HTC-PAL autosampler (CTC Analytics AG, Zwingen, Switzerland) connected to an Agilent 1100 binary pump (Agilent Technologies, Palo Alto, CA). The peptides were trapped on a precolumn (45 × 0.075-mm inner diameter) and separated on a reversed phase column, 200 × 0.050 mm. The flow through of the analytical column was reduced by a split to an ~100 nl/min. A 40-min gradient 10–50% CH3CN in 0.2% COOH was used for separation of the peptides.

The nanoflow LC-MS/MS was performed on a hybrid linear ion trap–FT/ICR mass spectrometer equipped with a 7T ICR magnet (LTQ-FT; Thermo Electron, Bremen, Germany). For each scan of FT/ICR, the three most intense, doubly or triply charged ions were sequentially fragmented in the linear trap by collision-induced dissociation. All of the tandem mass spectra were searched by MASCOT (Matrix Science, London). For protein identification, the minimum criteria were one tryptic peptide matched at or above the 99% level of confidence and an additional one peptide match at the 95% level.

Antigen Uptake Assays—Fel d 1 was labeled with Cyanine 5 (Cy5) (Amersham Biosciences) according to the manufacturer’s instructions. Uptake assays were carried out in medium consisting of RPMI (Sigma), 30% PBS with Ca2+ and Mg2+ (Invitrogen), and 5% FBS (Autogen Bioclear). Immature MoDCs (2 × 106/200 µl) were preincubated for 30 min with different concentrations (50, 100, 200, or 500 µg/ml) of SO4-3-Gal-PAA or Gal-PAA (Lectinity, Moscow, Russia) or mannann (200 µg/ml) and subsequently incubated with 5 µg/ml of Cy5 Fel d 1 for another 30 min. In some experiments, BM-DCs (2 × 106/200 µl) from WT and MR−/− mice were incubated with Cy5 Fel d 1 for 30 min, whereas in other experiments, Mo-DCs (1 × 106/100 µl) that have previously been treated with control (CT) or MR siRNA were incubated with 5 µg/ml of Cy5 Fel d 1 or FITC-Lewis-A-PAA (Lectinity) for 30 min. The cells were then
The Mannose Receptor Contributes to Fel d 1 Allergenicity

RESULTS

MR Expression Is Required for Uptake of Fel d 1 by Human DCs—To investigate the contribution of MR to Fel d 1 uptake by human DCs, we used a gene silencing strategy to specifically inhibit the expression of MR on human DCs as described in our previous work (28). MR was successfully down-regulated on DCs by siRNA with percentages of inhibition approaching 70–75% as shown by quantitative real time PCR (Fig. 1A). Western blotting (Fig. 1B), and flow cytometry (Fig. 1C). Immature Mo-DCs that had previously been treated with CT or MR siRNA were incubated with Cy5 Fel d 1, and Fel d 1 uptake was assessed by flow cytometry. We observed a significant inhibition (80%) of Fel d 1 uptake (Fig. 1D) by MR-deficient (mean fluorescence intensity = 83.85 ± 26.78) compared with MR-sufficient (mean fluorescence intensity = 421.9 ± 140.7) DCs. To confirm the specificity of the gene silencing, we used a polyclonal antibody against Lewis* antigen, a specific ligand for DC-SIGN, as a control, and no inhibition of uptake was observed (Fig. 1E). These results indicate that Fel d 1 uptake by human DCs is MR-mediated.
The Mannose Receptor Contributes to Fel d 1 Allergenicity

Fel d 1 Uptake by Human DCs Is Inhibited by Ligands for the CR Domain of MR—We then investigated the ability of SO₄³⁻Gal-PAA and mannan, specific ligands for the CR domain and the CTLD4–7 regions of MR, respectively, to inhibit Fel d 1 uptake by human DCs. Immature Mo-DCs were preincubated with different concentrations (50, 100, or 200 μg/ml) of SO₄³⁻Gal-PAA or mannan prior to the addition of labeled Cy5 Fel d 1. The results shown in Fig. 1 indicate that Fel d 1 uptake (mean fluorescence intensity) was inhibited in a dose-dependent manner by SO₄³⁻Gal-PAA (*p < 0.01, n = 3). The control ligand (Gal-PAA) had no effect on uptake. On the other hand, mannan, the control ligand for the CTLD4–7 region of MR, had no effect on Fel d 1 uptake by Mo-DCs (Fig. 1G), indicating that the CTLD4–7 domains of MR are not involved in Fel d 1 uptake by Mo-DCs.

MR Mediates the Uptake of Fel d 1 by Mouse Macrophages and DCs—To investigate whether the results obtained with human DCs translate to the mouse system, we investigated Fel d 1 uptake by mouse DCs and macrophages generated from WT and MR⁻/⁻ animals. The results shown in Fig. 2 demonstrate that both DCs (Fig. 2A and C) and macrophages (Fig. 2B) from MR-deficient animals display a major reduction in their ability to internalize Fel d 1, demonstrating that MR is a major receptor for Fel d 1 in mouse cells.

Fel d 1 Binds to the CR Domain of MR—To investigate whether the CR domain of MR could directly bind Fel d 1, we performed ELISA experiments using Fc-derived proteins bearing different domains of mouse MR (Fig. 3A). These assays showed that Fel d 1 binds strongly to CR-Fc, CR-FNII-CTLD1–Fic, and CR-FNII-CTLD1–3-Fc but not to CTLD4–7-Fc. None of the proteins bound to the negative control Gal-PAA (p < 0.0001, n = 5). The control ligand for the CR domain (SO₄⁴⁻3-Gal-PAA) showed strong binding to CR-Fc but not to CTLD4–7-Fc, whereas mannan showed strong binding to CTLD4–7-Fc and no binding to CR-Fc or CR-FNII-CTLD1–Fic and CR-FNII-CTLD1–3-Fc (n = 5). These results demonstrate that Fel d 1 is a ligand for the CR domain of MR. Further assays showed that Fel d 1 binds the CR domain in a dose-dependent manner (Fig. 3B).
To further corroborate the binding of Fel d 1 to the CR domain of MR, inhibition ELISA was performed whereby CR-Fc was incubated with different concentrations of SO₄⁻³-Gal-PAA or mannan prior incubation with Fel d 1. The results obtained (Fig. 3C) demonstrate a dose-dependent inhibition of Fel d 1 binding to CR-Fc by SO₄⁻³-Gal-PAA, whereas mannan did not show any effect.

**Glycan Composition of Natural Fel d 1**—To identify the carbohydrates present in Fel d 1 responsible for binding to the CR domain of MR, we determined the carbohydrate content of Fel d 1 using mass spectroscopic analysis. Fel d 1 is a 35-kDa tetrameric glycoprotein formed by two heterodimers. Each dimer is composed of two chains (chain 1 and 2) derived from two independent genes (38, 39). In agreement with the primary amino acid sequence predicting a single N-glycosylation site at Asn³³, we identified the single glycopeptide VNATEPER within Fel d 1 (Fig. 4). This glycopeptide is located in an exposed region of the chain 2 between helix 2 and helix 3 according to Fel d 1 crystal structure (40). The glycan composition of Fel d 1 comprises hybrid and complex carbohydrate structures containing sialic acid and, most importantly, sulfated moieties (Table 1). Supplemental Fig. S1 shows a representative collision-induced dissociation product ion spectrum of the tryptic glycopeptide MH⁺ = 3776.46. The presence of sulfate groups in the glycans associated with Fel d 1 is consistent with the capacity of Fel d 1 to bind the CR domain of MR.
The Mannose Receptor Contributes to Fel d 1 Allergenicity

MR Recognition Contributes to Fel d 1 Allergenicity in Vivo—

To investigate whether the capacity of Fel d 1 to bind MR could contribute to its allergenicity, we compared the response of WT and MR<sup>−/−</sup> mice to Fel d 1 sensitization. WT animals produced significantly (p < 0.05) higher total IgE levels (803.7 ± 180.5 ng/ml) compared with MR<sup>−/−</sup> animals (301.7 ± 64.94 ng/ml), whereas control mice, mock sensitized with PBS, produced undetectable levels of IgE (<0.5 ng/ml) (Fig. 5A). This difference in total IgE levels between WT and MR<sup>−/−</sup> mice was accompanied by a more significant difference (p < 0.01) for Fel d 1-specific IgG1 (p < 0.001; Fig. 5C) between the two groups of mice. Despite the low levels of Fel d 1-specific IgG2a that could be detected, as expected in a Th2-dominated response, WT mice produced significantly lower levels of IgG2a compared with WT mice (p < 0.03) (Fig. 5D). These results indicate that the allergenic potential of Fel d 1 is enhanced by its capacity to bind MR.

DISCUSSION

Dendritic cells are sentinels of the immune system with superior ability for antigen recognition and uptake, as well as for priming naïve T cells (41). Cat allergy affects ~10–15% of the adult population (7), and 20–30% of asthmatic individuals respond to cat allergen exposure (42, 43). Moreover, it has also been shown that up to 40% of asthmatic children are sensitized to cat (1, 44).

In a recent study, we demonstrated that MR is a common receptor on human DCs for the uptake of a number of clinically relevant allergens from diverse sources (28). In this study, we have shown the key role of MR in Fel d 1 uptake by antigen-presenting cells through gene knockdown experiments that specifically target MR and using BM-DC and macrophages obtained from WT and MR<sup>−/−</sup> mice. These have shown that MR-deficient DCs displayed a significantly reduced capacity to internalize Fel d 1 as compared with MR-sufficient DCs. The substantial reduction/abrogation in Fel d 1 uptake observed with the MR-deficient cells suggests that MR is the main, and most likely the sole, endocytic receptor for the uptake of Fel d 1 by human and mouse antigen-presenting cells. Furthermore, we have identified Fel d 1 as a novel ligand for the CR domain of MR. This was unexpected, because all other tested allergens (Der p 1, Der p 2, Ara h 1, Can f 1, and Bla g 2) have previously been shown to be recognized by the CTLD4–7 domains of MR (28). To date, all other ligands described for the CR domain have been of endogenous origin (45, 46), and it is rather intriguing that the main source of Fel d 1, cat hair/dander, could contain ligands for MR. It is worth noting that Fel d 1 is a member of the secretoglobin family and, together with the hamster Harderian gland proteins and mouse salivary androgen-binding protein, is secreted by exocrine glands and is released to the exterior as a result of licking and grooming (47). It would be of interest to see whether the CR domain could detect other ligands in exocrine organs of other organisms.

Previous studies have identified the major cat allergen, Fel d 1, as a 35-kDa tetrameric glycoprotein with one N-glycosylation site located at residue Asn<sup>13</sup> in chain 2 (38, 48). Other studies identified three important IgE epitopes in Fel d 1: two in chain 1 and one in chain 2 (49). The present work shows that Fel d 1 contains a complex glycosylation pattern characterized by the presence of sulfated sugars, as revealed by proteomic (mass spectrometric) analysis (Table 1), and no such glycan structure

![Diagram](image)
has previously been reported for glycoallergens. This sulfated sugar moiety may therefore function as a molecular pattern that could be recognized by the CR domain of MR. Moreover, mass spectroscopic analysis of Fel d 1 revealed reduced presence of mannose-type carbohydrate structures. This, therefore, explains our findings regarding the inability of Feld1 to bind to the CTLD4–7 domains of MR.

Experimentally induced allergy using either purified Fel d 1 or cat dander extract has previously been reported (37, 50). Following a similar sensitization regime and using WT and MR/H11002/H11002 mice, we investigated whether MR plays a role in deviating the immune response toward a Th2 phenotype after exposure to Fel d 1. Levels of total and allergen-specific IgE were measured as indicators for allergic sensitization (51–54). Measurements of IgG2a (Th1) and IgE and IgG1 (Th2) were used as markers for their respective Th subset responses (55–57).

Interestingly, MR/H11002/H11002 mice produced significantly less total IgE, Fel d 1-specific IgE and IgG1 than WT mice sensitized under similar conditions. By contrast, MR/H11002/H11002 mice produced significantly higher amounts of Fel d 1-specific IgG2a, the Th1-dependent isotype, compared with WT mice. These findings clearly indicate for the first time that MR has a major role in mediating Th2 polarization to an airborne allergen in an in vivo setting. This study and our previous work involving human in vitro experiments point strongly to the central role played by MR in allergic sensitization to multiple glycolallergens.

Identifying putative receptors on antigen-presenting cells that play a central role in allergen uptake and downstream events leading to IgE production could certainly lead to better understanding of early events leading to allergic sensitization and pave the way for the rational design of novel therapeutic strategies.

Acknowledgments—We thank the Proteomics Center at Sahlgrenska Academy (funded by a grant from the Knut and Alice Wallenberg Foundation) (University of Gothenburg) for technical assistance with regard to Glycan analysis and Nanoflow LC-MS/MS Fourier Transform Ion Cyclotron Resonance experiments.

REFERENCES
1. Gelber, L. E., Seltzer, L. H., Bouzoukis, J. K., Pollart, S. M., Chapman, M. D., and Platts-Mills, T. A. (1993) Am. Rev. Respir. Dis. 147, 573–578
2. Platts-Mills, T. A., Vervloet, D., Thomas, W. R., Aalberse, R. C., and Chapman, M. D. (1997) J. Allergy Clin. Immunol. 100, S2–24
3. Ichikawa, K., Iwasaki, E., Baba, M., and Chapman, M. D. (1999) Clin. Exp. Allergy 29, 754–761
4. Roost, H. P., Künzli, N., Schindler, C., Jarvis, D., Chinn, S., Perruchoud, A. P., Ackermann-Liebrich, U., Burney, P., and Wüthrich, B. (1999) J. Allergy Clin. Immunol. 104, 941–947
5. Lowenstein, H., Lind, P., and Weeke, B. (1985) Allergy 40, 430–441
6. de Groot, H., van Swieten, P., van Leeuwen, J., Lind, P., and Aalberse, R. C. (1988) J. Allergy Clin. Immunol. 82, 778–786
7. Kleine-Tebbe, J., Kleine-Tebbe, A., Jeep, S., Schou, C., Lowenstein, H., and Kunkel, G. (1993) Int. Arch. Allergy Immunol. 100, 256–262
8. Addéoyin, J., Grönlund, H., Oman, H., Johannson, S. G., and van Hage, M. (2007) J. Allergy Clin. Immunol. 119, 640–645
9. Banchereau, J., and Steinman, R. M. (1998) Nature 392, 245–252
10. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. I., Pulendran, B., and Palucka, K. (2000) Annu. Rev. Immunol. 18, 767–811
11. McGreal, E. P., Miller, J. L., and Gordon, S. (2005) Curr. Opin. Immunol. 17, 18–24
12. Cambi, A., Koopman, M., and Figdor, C. G. (2005) Cell Microbiol. 7, 481–488
The Mannose Receptor Contributes to Fel d 1 Allergenicity

1040 JOURNAL OF BIOLOGICAL CHEMISTRY

13. Giizjen, K., Cambi, A., Torensma, R., and Figdor, C. G. (2006) Curr. Protein

Pept. Sci. 7, 283–294

14. Engering, A. J., Cella, M., Fluitsma, D. M., Hoefsmit, E. C., Lanzavecchia,

A., and Pieters, J. (1997) Adv. Exp. Med. Biol. 417, 183–187

15. Deslée, G., Charbonnier, A. S., Hammad, H., Angyalosi, G., Tillie-Leblond,

I., Mantovani, A., Tonnel, A. B., and Pestel, J. (2002) J. Allergy Clin. Immunol.

110, 763–770

16. Syrne, R. M., Spurrell, J. C., Amankwah, E. K., Green, F. H., and Mody,

C. H. (2002) Infect. Immun. 70, 5972–5981

17. Cambi, A., and Ezekowitz, R. A. (1998) Curr. Opin. Immunol. 10, 50–55

18. Harris, N., Super, M., Rits, M., Chang, G., and Ezekowitz, R. A. (1992) Blood

80, 2363–2373

19. Taylor, M. E., Bezouska, K., and Drickamer, K. (1992) J. Biol. Chem. 267,

1719–1726

20. Mulllin, N. P., Hall, K. T., and Taylor, M. E. (1994) J. Biol. Chem. 269,

28405–28413

21. Taylor, P. R., Gordon, S., and Martinez-Pomares, L. (2005) Trends Immunol.

26, 104–110

22. Napper, C. E., Drickamer, K., and Taylor, M. E. (2006) Biochem. J. 395,

579–586

23. Martinez-Pomares, L., Wienke, D., Stillion, R., McKenzie, E. J., Arnold,

J. N., Harris, J., McGreel, E., Sim, R. B., Isacke, C. M., and Gordon, S. (2006)

Eur. J. Immunol. 36, 1074–1082

24. Royer, P. J., Emara, M., Yang, C., Al-Ghouleh, A., Tighe, P., Jones, N., Sewell,

H. F., Shakh, F., Martinez-Pomares, L., and Ghaemmaghami, A. M. (2010) J. Immunol.

185, 1522–1533

25. Horlock, C., Shakh, F., Mahdavi, J., Jones, N. S., Sewell, H. F., and Ghaem-

maghami, A. M. (2007) Genome Biol. 8, R30.1–R30.13

26. Inaba, K., Swiggard, W. J., Steinman, R. M., Romani, N., Schuler, G., and

Brinster, C. (2009) Curr. Protoc. Immunol. 86, 37.1–37.19

27. Peiser, L., Gough, P. J., Kodama, T., and Gordon, S. (2008) Infect. Immun.

66, 1953–1963

28. Chapman, M. D., Aalberse, R. C., Brown, M. J., and Platt's-Mills, T. A.

(1988) J. Immunol. 140, 812–818

29. Martinez-Pomares, L. (2009) Methods Mol. Biol. 531, 103–122

30. Carlsohn, E., Nyström, J., Karlsson, H., Svennerholm, A. M., and Nilsson,

C. L. (2006) J. Proteome Res. 5, 3197–3204

31. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996) Anal. Chem.

68, 850–858

32. Lee, S. J., Evers, S., Roeder, D., Parlow, A. F., Risteli, J., Risteli, L., Lee, Y. C.,

Feizi, T., Langen, H., and Nussenzweig, M. C. (2002) Science 295,

1898–1901

33. Campbell, J. D., Buckland, K. F., McMillan, S. J., Kearley, J., Oldfield, W. L.,

Stern, L. I., Grönlund, H., van Hage, M., Reynolds, C. J., Boyton, R. J.,

Cobbold, S. P., Kay, A. B., Altmann, D. M., Lloyd, C. M., and Larché, M.

(2009) J. Exp. Med. 206, 1535–1547

34. Kristensen, A. K., Schou, C., and Roepstorff, P. (1997) Biol. Chem. 378,

899–908

35. Griffith, J. I., Craig, S., Pollock, J., Yu, X. B., Morgenstern, J. P., and Rogers,

B. L. (1992) Gene 113, 263–268

36. Kaiser, L., Grönlund, H., Sandalova, T., Ljunggren, H. G., van Hage-Ham-

sten, M., Achour, A., and Schneider, G. (2003) J. Biol. Chem. 278,

37730–37735

37. Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., and Amigorena, S.

(2002) Annu. Rev. Immunol. 20, 621–667

38. Liam, C. K., Loo, K. L., Wong, C. M., Lim, K. H., and Lee, T. C. (2002) Respirology

7, 345–350

39. Sarsfield, J. K., Boyle, A. G., Rowell, E. M., and Morriarty, S. C. (1976) Arch.

Dis. Child. 51, 186–189

40. Custovic, A., Simpson, A., Pahdi, H., Green, R. M., Chapman, M. D., and

Woodcock, A. (1998) Thorax 53, 33–38

41. Fiete, D. J., Bernake, M. C., and Baenzerger, J. U. (1998) Proc. Natl. Acad.

Sci. U.S.A. 95, 2089–2093

42. Leteux, C., Chai, W., Loveless, R. W., Yuen, C. T., Uhlin-Hansen, L., Com-
barnous, Y., Jankovic, M., Marc, S. C., Misulovin, Z., Nussenzweig, M. C.,

and Feizi, T. (2000) J. Exp. Med. 191, 1117–1126

43. Karn, R. C., and Laukaitis, C. M. (2003) Biochemistry 42, 7162–7170

44. Duftoff, O. A., Carreira, J., Nitti, G., Polo, F., and Lombardero, M. (1991)

J. Allergy Clin. Immunol. 88, 301–309

45. van Milligen, F. J., van 't Hof, W., van den Berg, M., and Aalberse, R. C.

(1994) J. Allergy Clin. Immunol. 93, 34–43

46. Terada, T., Zhang, K., Belperio, J., Londhe, V., and Saxon, A. (2006)

J. Immunol. 176, 1117–1126

47. Cobbold, S. P., Kay, A. B., Altmann, D. M., Lloyd, C. M., and Feizi, T. (2000)

Curr. Protein Pept. Sci. 1, 189–199

48. Glovsky, M. M. (2007) Methods Mol. Biol. 378, 205–219

49. Niggemann, B., Nilsson, M., and Friedruchs, F. (2008) Pediatr. Allergy Immunol.

19, 325–331

50. Mountford, A. P., Fisher, A., and Wilson, R. A. (1994) Parasite Immunol.

16, 521–527

51. Ade-Patient, K., Crémillon, C., Bernard, H., Clément, G., Négroni, L.,

Frobert, Y., Grassi, J., Wal, J. M., and Chatel, J. M. (2000) J. Immunol.

Methods 235, 21–32

52. Ormstad, H., Groeng, E. C., Duftoff, O., and Løvik, M. (2003) Toxicology

189, 309–318